Personalised cancer vaccine cuts melanoma return risk by 42% in major trial

A personalised cancer vaccine given with a common immunotherapy drug cut the risk of melanoma patients dying or their cancer returning by 42% in a large trial. The combination also lowered the risk of spread by 38% over two years. Makers MSD and Moderna are testing the approach on kidney, bladder and lung cancers, while experts call for longer-term studies.